Atrinsic (PTIX) Stock Price, News & Analysis

Company Overview

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: $3.41 to $3.59
• 50-Day Range: $2.85 to $11.10
• 52-Week Range: $2.35 to $15.54
• Volume: 60,478 shs
• Average Volume: 561,661 shs
• Market Capitalization: $2.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Atrinsic Stock Analysis - MarketRank™

Atrinsic scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Atrinsic.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Atrinsic is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atrinsic is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atrinsic has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.97% of the float of Atrinsic has been sold short.

Short Interest Ratio / Days to Cover

Atrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atrinsic has recently decreased by 65.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atrinsic does not currently pay a dividend.

Dividend Growth

Atrinsic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.97% of the float of Atrinsic has been sold short.

Short Interest Ratio / Days to Cover

Atrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atrinsic has recently decreased by 65.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for PTIX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Atrinsic to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atrinsic insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.00% of the stock of Atrinsic is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.97% of the stock of Atrinsic is held by institutions.

PTIX Stock Analysis - Frequently Asked Questions

How have PTIX shares performed this year?

Atrinsic's stock was trading at $6.86 at the start of the year. Since then, PTIX stock has decreased by 49.9% and is now trading at $3.44.
View the best growth stocks for 2025 here.

How were Atrinsic's earnings last quarter?

Atrinsic Inc. (NASDAQ:PTIX) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($2.75) EPS for the quarter.

When did Atrinsic's stock split?

Shares of Atrinsic reverse split on the morning of Monday, May 5th 2025. A 1-14 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Atrinsic?

Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atrinsic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atrinsic investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), NVIDIA (NVDA), Cytokinetics (CYTK), Heatwurx (PCSA), Acasti Pharma (ACST) and Akero Therapeutics (AKRO).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/20/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTIX
• CIK: 1022899
• Web: www.protagenic.com
• Phone: 212-994-8200
• Fax: 603-761-6223
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($13.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.53 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -860.52%
• Return on Assets: -354.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.96 per share
• Price / Book: 1.76

Miscellaneous

• Outstanding Shares: 590,000
• Free Float: 383,000
• Market Cap: $2.03 million
• Optionable: Not Optionable
• Beta: 0.36